4.3 Article

Pharmacological treatment of asthma in a cohort of adults during a 20-year period: results from the European Community Respiratory Health Survey I, II and III

期刊

ERJ OPEN RESEARCH
卷 5, 期 1, 页码 -

出版社

EUROPEAN RESPIRATORY SOC JOURNALS LTD
DOI: 10.1183/23120541.00073-2018

关键词

-

资金

  1. European Commission [018996]
  2. Asthma Foundation of Victoria, Allen and Hanburys
  3. Belgian Science Policy Office, National Fund for Scientific Research
  4. Estonian Science Foundation [1088]
  5. Glaxo France
  6. Contrat de Plan Etat-Region Languedoc-Rousillon, CNMATS
  7. CNMRT [90MR/10, 91AF/6]
  8. Ministre delegue de la sante, RNSP, France
  9. Bundesminister fur Forschung und Technologie
  10. Greek Secretary General of Research and Technology, Fisons
  11. Boehringer Ingelheim
  12. Ministero dell'Universita e della Ricerca Scientifica e Tecnologica, CNR [RSF 381/05.93]
  13. Netherlands: Dutch Ministry of Wellbeing, Public Health and Culture and the Netherlands Asthma Foundation
  14. Norwegian Research Council [214123]
  15. Glaxo Farmaceutica Lda, Sandoz Portugesa
  16. Fondo de Investigacion Sanitaria
  17. (Consejeria de Sanidad del Principado de Asturias) [1997 SGR 00079]
  18. Servicio Andaluz de Salud
  19. Swedish Medical Research Council
  20. Swedish Heart Lung Foundation
  21. Swedish Association against Asthma and Allergy
  22. Swiss National Science Foundation [33CSCO-134276/1, 33CSCO-108796, 3247BO-104283, 3247BO-104288, 3247BO-104284, 3247-065896, 3100-059302, 3200-052720, 3200-042532, 4026-028099]
  23. UK: National Asthma Campaign
  24. British Lung Foundation
  25. Dept of Health, South Thames Regional Health Authority
  26. National Health and Medical Research Council
  27. Fund for Scientific Research [G.0402.00]
  28. Flemish Health Ministry
  29. Tartu Estonian Science Foundation [4350]
  30. Programme Hospitalier de Recherche Clinique-Direction de la Recherche Clinique (DRC) de Grenoble [2610]
  31. Direction Generale de la Sante
  32. Direction Regionale des Affaires Sanitaires et Sociales Languedoc-Roussillon
  33. Aventis
  34. GSF-National Research Centre for Environment and Health, Deutsche Forschungsgemeinschaft [MA 711/4-1]
  35. Icelandic Research Council, Icelandic University Hospital Fund
  36. Italian Ministry of University and Scientific and Technological Research (MURST), Local University Funding for Research [1998, 1999]
  37. Turin: Azienda Sanitaria Locale 4 Regione Piemonte (Italy), Azienda Ospedaliera Centro Traumatologico Ospedaliero/Centro Traumatologico Ortopedico-Istituto Clinico Ortopedico Regina Maria Adelaide Regione Piemonte
  38. Ministero dell'Universita e della Ricerca Scientifica (MURST)
  39. Glaxo Wellcome SpA
  40. Norwegian Asthma and Allergy Association
  41. Glaxo Wellcome AS, Norway Research Fund
  42. Fondo de Investigacion Santarias [97/0035-01, 99/0034-01, 99/0034 02]
  43. Hospital Universitario de Albacete, Consejeria de Sanidad
  44. Fondo de Investigaciones Santarias [97/0035-01, 99/0034-01, 99/0034-02]
  45. Consell Interdepartamental de Recerca i Innovacio Tecnologica [1999SGR 00241]
  46. Instituto de Salud Carlos III: Red de Centros de Epidemiologia y Salud Publica [C03/09]
  47. Red de Bases moleculares y fisiologicas de las Enfermedades Respiratorias [C03/011, G03/176]
  48. Basque Health Dept Oviedo: Fondo de Investigaciones Sanitaria [99/0034-01, 97/0035-02, 97/0035, 99/0034-04, 99/0034-06, 99/350, 99/0034-07]
  49. Generalitat de Catalunya [97/0035-01, 99/0034-01, 99/0034-02, C03/09, C03/011, G03/176, CIRIT 1999 SGR 00214, SEPAR R01 HL62633-01]
  50. Swedish Foundation for Health Care Sciences and Allergy Research
  51. Swedish Asthma and Allergy Foundation
  52. Swedish Cancer and Allergy Foundation
  53. Swedish Council for Working Life and Social Research (FAS)
  54. Swiss Federal Office for Education and Science, Swiss National Accident Insurance Fund
  55. UK: Asthma UK
  56. Medical Research Council [92091]
  57. Research Foundation Flanders (FWO) [SF0180060s09]
  58. Estonian Ministry of Education
  59. Ministere de la Sante
  60. Programme Hospitalier de Recherche Clinique (PHRC)
  61. Paris: Agence Nationale de la Sante
  62. Region Ile de France
  63. Germany: Erfurt: German Research Foundation [HE 3294/10-1]
  64. German Research Foundation [MA 711/6-1, 262/7-1]
  65. Landspitali University Hospital Research Fund, University of Iceland Research Fund
  66. ResMed Foundation (CA, USA)
  67. Vegageroin (The Icelandic Road Administration) - Cariverona Foundation, Education Ministry (MIUR)
  68. Western Norway Regional Health Authorities [911631]
  69. Bergen Medical Research Foundation
  70. Sociedad Espanola de Neumologia y Cirurgia Toracica [SEPAR 1001/2010]
  71. Barcelona: Fondo de Investigacion Sanitaria [PS09/00716]
  72. Galdakao: Fondo de Investigacion Sanitaria [09/01511]
  73. Huelva: Fondo de Investigacion Sanitaria [PS09/02185, PS09/03190]
  74. Swedish Heart and Lung Foundation
  75. Swedish Asthma and Allergy Association
  76. Swedish Association against Lung and Heart Disease
  77. Swedish Research Council for Health, Working Life and Welfare (FORTE)
  78. Swedish Council for Working Life and Social Research
  79. Umea: Vasterbotten Country Council ALF grant
  80. Federal Office for Forest
  81. Federal Office of Roads and Transport, the Canton's Government of Aargan, Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino, Valais and Zurich
  82. Swiss Lung League
  83. Canton's Lung League of Basel-Stadt/Basel, Landschaft, Geneva, Ticino, Valais and Zurich
  84. Freiwillige Akademische Gesellschaft
  85. UBS Wealth Foundation
  86. Talecris Biotherapeutics GmbH
  87. Abbott Diagnostics
  88. Wellcome Trust [WT 084703MA]
  89. UK: Medical Research Council [92091]
  90. National Institute for Health Research through the Primary Care Research Network
  91. MRC [G0901214] Funding Source: UKRI

向作者/读者索取更多资源

Asthma often remains uncontrolled, despite the fact that the pharmacological treatment has undergone large changes. We studied changes in the treatment of asthma over a 20-year period and identified factors associated with the regular use of inhaled corticosteroid (ICS) treatment. Changes in the use of medication were determined in 4617 randomly selected subjects, while changes in adults with persistent asthma were analysed in 369 participants. The study compares data from three surveys in 24 centres in 11 countries. The use of ICSs increased from 1.7% to 5.9% in the general population and the regular use of ICSs increased from 19% to 34% among persistent asthmatic subjects. The proportion of asthmatic subjects reporting asthma attacks in the last 12 months decreased, while the proportion that had seen a doctor in the last 12 months remained unchanged (42%). Subjects with asthma who had experienced attacks or had seen a doctor were more likely to use ICSs on a regular basis. Although ICS use has increased, only one-third of subjects with persistent asthma take ICSs on a regular basis. Less than half had seen a doctor during the last year. This indicates that underuse of ICSs and lack of regular healthcare contacts remains a problem in the management of asthma.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据